DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

DexCom, Inc. (DXCM) Securities Class Action: DexCom, a leading provider of continuous glucose monitoring systems, is under intense scrutiny from investors and analysts following a disappointing ...

DexCom Inc (DXCM) stock saw a decline, ending the day at $68.94 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.09. The stock opened at $69.99 and touched a low of $68.59 ...

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to ...

However, it's not what Alphabet holds that's raising eyebrows. Rather, it's the two core artificial intelligence (AI) stocks ...

NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...